¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"spin phase effect"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • side effect
    ºÎÀÛ¿ë
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
  • active phase
    Ȱ¼º±â
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • anal-sadistic phase
    Ç×¹®°¡Çбâ
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • circadian-phase intervention
    ÇÏ·çÁÖ±âÀ§»óÁßÀç
  • colostral phase
    ÃÊÀ¯±â, ùÁ¥¼·Ãë±â
  • compression phase
    ¾ÐÃà»ó
  • delayed sleep phase
    ¼ö¸éÀ§»óÁö¿¬
  • delayed sleep phase syndrome
    ¼ö¸éÀ§»óÁö¿¬ÁõÈıº
  • depressive phase
    ¿ì¿ï»ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • polar effect
    ±Ø¼ºÈ¿°ú
  • polarizing effect
    ºÐ±ØÈ¿°ú
  • pooling effect
    Àú·ùÈ¿°ú
  • priming effect
    ½Ãµ¿È¿°ú
  • prolonged effect
    Áö¼ÓÈ¿°ú, Áö¿¬È¿°ú
  • radiation effect
    ¹æ»ç¼±È¿°ú
  • radio-frequency thermal effect
    °íÁÖÆÄ¿­È¿°ú
  • radioactive effect
    ¹æ»ç´ÉÈ¿°ú
  • radiologic biologic effect
    ¹æ»ç¼±»ýüȿ°ú
  • resonance effect
    °ø¸íÈ¿°ú
  • reversing effect
    ¿ªÀüÈ¿°ú
  • rush effect
    ¼âµµÈ¿°ú
  • shielding effect
    Â÷ÆóÈ¿°ú, °¡¸²È¿°ú
  • shunt effect
    Áö¸§±æÈ¿°ú, ¼ÇƮȿ°ú
  • sialagogic effect
    ħºÐºñÃËÁøÈ¿°ú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • g2 phase
    ÇÕ¼ºÈıâ G2±â
  • gastric phase
    À§»ó(êÖßÓ) À§»êºÐºñ(êÖߤÝÂÝô)ÀÇ .
  • go phase
    Á¤Áö±â Go±â
  • grinding phase
    ºÐ¼â»ó.
  • implantational phase
    Âø»ó±â
  • in-phase image
    À§»ó³» ¿µ»ó
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inspiratory phase
    Èí±â»ó(ýåѨßÓ).
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • phallic stage (phase)
    ³²±Ù±â(ÑûÐÆÑ¢).
  • phase
    »ó, ±â
  • phase
    ˤȗ
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • doppler effect
    µµÇ÷¯ È¿°ú (üùÍý)
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose-effect relationship
    ¼±·®¿µÇâ°ü°è
  • double effect
    ÀÌÁßÈ¿°ú
  • drug effect
    ¾à¹°È¿°ú
  • drying effect
    °ÇÁ¶È¿°ú(ËëðÏüùÍý).
  • dual effect
    ÀÌ»ó¼º(ÀÌÁß)È¿°ú.
  • dual effect
    ÀÌ»ó¼º(ì¶ßÒàõ)(ÀÌÁß)È¿°ú.
  • early effect
    Á¶±âÈ¿°ú
  • edge effect
    ¿¬È¿°ú(æÞüùÍý).
  • edge effect
    ¸ð¼­¸®È¿°ú
  • effect
    È¿°ú, ÀÛ¿ë.
  • effect concentration(=activity)
    À¯È¿³óµµ(êóüùÒØÓø)
  • effect, Pasteur
    ÆÄ½ºÆ©¸£È¿°ú
  • effect, cytopathogenic
    ¼¼Æ÷º´º¯È¿°ú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • photoelectric effect
    ±¤ÀüÈ¿°ú(ÎÃï³üùÍý)
  • piezoelectric effect
    ¾ÐÀü±âÈ¿°ú(äâï³Ñ¨üùÍý)
  • pressor effect
    Ç÷¾Ð È¿°ú(úìäâüùÍý)
  • primary charge effect
    ÀÏÂ÷ ÀüÇÏÈ¿°ú(ìéó­ï³ùÃüùÍý)
  • primary isotope effect
    ÀÏÂ÷ µ¿À§¿ø¼Ò È¿°ú(ìéó­ÔÒêÈêªáÈüùÍý)
  • propinquit effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • proximity effect
    ±ÙÁ¢È¿°ú(ÐÎïÈüùÍý)
  • Raman effect
    ¶ó¸¸ È¿°ú(üùÍý)
  • relaxation effect
    ÀÌ¿Ï È¿°ú(ì¬èÐüùÍý)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
  • sparing effect
    ¿¹ºñÈ¿°ú(çãÝáüùÍý)
  • spreading position effect
    ÆÛÁü À§Ä¡ È¿°ú(êÈöÇüùÍý)
  • Stark effect
    ½ºÅ¸Å© È¿°ú(üùÍý)
  • thyrotoxic effect
    °©»ó¼±Áßµ¶ È¿°ú (Ë£ßÒàÍñéÔ¸üùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • phase contrast
    À§»ó´ëÁ¶
  • phase contrast MR angiography
    À§»ó´ëÁ¶ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • phase curve
    À§»ó°î¼±
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
  • phase encoding
    À§»óºÎȣȭ
  • phase encoding gradient
    À§»óºÎȣȭ°æ»çµµ(Àå)
  • phase encoding step
    À§»óºÎÈ£´Ü°è
  • phase evolution of fat suppression
    À§»ó¼±È¸ Áö¹æ¾ïÁ¦
  • phase frequency swap
    À§»óÁ֯ļö±³È¯
  • phase image
    À§»ó¿µ»ó
  • phase mismapping
    À§»ó¿ÀÁöµµÀÛ¼º
  • phase offset multiplannar [=POMP] imaging
    À§»ó¿ÀÇÁ¼Â´Ù¸é¿µ»ó
  • phase sensitive technique description
    À§»ó¹Î°¨¹ý¼³¸í
  • phase shift
    À§»óº¯À§
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
FET field-effect transistor; forced expiratory time
HWE healthy worker effect; hot water extract
IGFET insulated gate field effect transistor
ITE insufficient therapeutic effect; in the ear [hearing aid]; in-training examination; intrapulmonary i...
JFET junction field effect transistor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
NOEL No Observed Effect Level
NOEC No observed effect concentration
NOE Nuclear Overhauser Effect
NOESY Nuclear Overhauser Effect spectroscopy
PEV Position effect variegation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • detergent effect
    Á¤È­ ÀÛ¿ë
  • domino effect
    µµ¹Ì³ë È¿°ú
  • Donnan effect
    µµ³­ È¿°ú
  • Doppler effect
    µµÇ÷¯ È¿°ú, Doppler È¿°ú
    1. ±Ù¿øÁö¿¡ ´ëÇÑ ¼ö½ÅÁöÀÇ »ó´ëÀûÀÎ ¿îµ¿À¸·ÎºÎÅÍ ¾ß±âµÇ´Â Á֯ļöÀÇ ¸í¹éÇÑ º¯È­. 2. ¾î¶² ¹°Ã¼°¡ ¿îµ¿ »óÅ¿¡ ÀÖÀ» ¶§ ³ªÅ¸³ª´Â ¹ÝÇâµÇ´Â ¹æ»ç¼±¿¡¼­ Áøµ¿¼öÀÇ º¯È­´Â µµÇ÷¯ È¿°úÀÇ °á°úÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ¸·ÎºÎÅÍ ¶³¾îÁø ¹°Ã¼ÀÇ ¿îµ¿Àº Á¤Áö »óÅÂÀÇ ¹°Ã¼¿¡ ºñ±³ÇØ º¼ ¶§ ´õ ³·Àº Áøµ¿¼öÀÇ ¹ÝÇâÀ» ÀÏÀ¸Å³ °ÍÀÌ´Ù. ¹æ»ç¼±ÀÇ ±Ù¿øÀ» ÇâÇÑ ¿îµ¿Àº ´õ ³ôÀº Áøµ¿¼ö¸¦ ÀÏÀ¸Å²´Ù.
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • double effect
    ÀÌÁß È¿°ú
  • drug side effect
    ºÎÀÛ¿ë
  • efferent effect
    ¿ø½É È¿°ú
  • entry slice effect
    À¯ÀÔ ´Ü¸é È¿°ú
  • first pass effect
    ÀÏÂ÷ Åë°ú È¿°ú
  • focus effect
    ÃÐÁ¡ È¿°ú
  • harmful effect
    À§ÇØ ÀÛ¿ë
    À§ÇèÇÑ ÀçÇØ. Á¶Á÷À̳ª »ý¸íü¿¡ ÇØ·Î¿î ¿µÇâÀ» ³¢Ä¡´Â ÀÛ¿ë.
  • heel effect
    Èú È¿°ú
    ¾ç±Ø °æ»ç °¢µµ¿¡ µû¸¥ È¿°ú.
  • indirect effect
    °£Á¢ È¿°ú
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
toxic effect <physiology> The physiologic, physical or laboratory manifestations or derangement that can be attributed to the presence of a substance within the body.
(12 Jan 1998)
enhancement effect Property of higher plant photosynthesis, discovered by Robert Emerson. The quantum yield of red light (less than 680nm) and far red light (700nm), when shone simultaneously on a plant, is greater than the sum of the yields of the light of the two wavelengths separately. This effect provides evidence for the cooperative interaction of two photosystems in photosynthesis.
(18 Nov 1997)
tunneling effect <radiobiology> In quantum mechanics, a particle approaching a potential energy barrier of finite extent has a chance (usually small) of tunneling through the barrier, even though it lacks the energy to go over the barrier. Tunneling plays a strong role in fusion reactions: particles which do not have enough energy to climb over the electrostatic energy barrier (into the region where nuclear attractions dominate) can still fuse by tunneling through.
(09 Oct 1997)
Tyndall effect The visibility of floating particles in gases or liquids when illuminated by a ray of sunlight and viewed at right angles to the illuminating ray.
Synonym: Tyndall effect.
(05 Mar 2000)
extrapyramidal effect A combination of neurologic effects which includes tremors, chorea, athetosis and dystonia. A common side effect of neuroleptic agents (phenothiazines). Other medications known to cause these reactions include haloperidol, molindone, perphenazine & amitriptyline, loxapine, pimozide and rarely, benzodiazepines.
(27 Sep 1997)
Fahraeus-Lindqvist effect The decrease in apparent viscosity that occurs when a suspension, such as blood, is made to flow through a tube of smaller diameter; observed in tubes less than about 0.3 mm in diameter.
Synonym: sigma effect.
(05 Mar 2000)
Zeeman effect The splitting of spectral lines into three or more symmetrically placed lines when the light source is subjected to a magnetic field.
(05 Mar 2000)
Fenn effect The increased liberation of heat in a stimulated muscle when it is allowed to do mechanical work; the amount of heat liberated is increased in proportion to the distance the muscle is allowed to shorten and in proportion to the tension it must develop (e.g., the weight it lifts) during shortening; thus increased chemical energy is consumed both to liberate increased heat and to do increased mechanical work.
(05 Mar 2000)
zygotic effect gene <genetics> A gene whose phenotype is dependent on the genotype of the zygote, rather than the genotype of the mother.
See: maternal effect gene.
(18 Nov 1997)
late effect Side effects of chemotherapy and/or radiotherapy which only become apparent with long-term monitoring of the patient over a period of years. These are of particular concern in patients below the age of puberty.
(18 Nov 1997)
founder effect The establishment of a new population by a few original founders (in an extreme case, by a single fertilized female) which carry only a small fraction of the total genetic variation of the parental population [Ernst Mayr, 1963]. The result is that a given allele, gene, chromosome, or part of a chromosome found in members of the population can be traced back to one ancestral individual.
(09 Oct 1997)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á